Partner With us
We are commercialising a pipeline of revolutionary PhMS-qPCR and LFT assays that will fundamentally improve the speed and accuracy of diagnosis of important mycobacterial diseases of humans and commercial livestock.
RAPIDvMAP
Rapid detection (≤ 8 hrs) of viable MAP in milk, faeces or blood, thereby diagnosing infectious animals with Johne’s disease. Combining the speed of ELISA screening assays with the accuracy of traditional confirmatory culture assays.
RAPIDbTB
Offers speedy and accurate detection of viable M. bovis in blood or faeces that is unmatched by currently available diagnostic techniques. The assay, which detects only ‘active’ infection, removes the (≥ 20%) threat of false positive results that occur with the intradermal skin test, and which confound M. bovis control and eradication programmes globally.
Livestock Applications
Read more about the applications for Johne’s Disease and Bovine Tuberculosis.
RAPIDTB
Definitive diagnosis and differentiation of ‘active’ zoonotic M. bovis from M. tuberculosis infection in less than a day (≤ 8 hrs) from an original patient sputum sample. This PhMS-duplex qPCR assay will radically transform global efforts to control and eradicate TB by enabling the immediate point of care administration of the most appropriate and effective antibiotic therapy.
RAPIDzTB
This complementary lateral flow test (LFT) will differentiate zoonotic M. bovis infection from infections caused by other M. tuberculosis complex species in less than 15 minutes from a positive patient culture sample.
The assay is designed for use in situations where access to confirmatory molecular techniques, such as spoligotyping are unavailable. RAPIDzTB will enable the administration of the most appropriate and effective antibiotic therapy for patients.
RAPIDvLEP
The first in-vitro molecular diagnostic technology will be able to definitively diagnose ‘active’ M. leprae infection from an original patient tissue, slit skin smear, urine or blood sample within 24-48 hours rather than ≥ 6 months for the current standard mouse footpad assay.
RAPIDvLEP will have the potential to transform the diagnosis and rapid antibiotic treatment of leprosy leading to better patient outcomes and reduced community spread of disease.
commercialisation partners
RMT has developed considerable IP and know-how in the development and manufacture of its PhMS-qPCR and LFT diagnostic assays and is now preparing for full commercial launch.
We encourage approaches from prospective commercialisation partners who are keen to understand more about the commercial potential of our technology and products